Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
about
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemiaPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Regulation of Bim in Health and DiseaseKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaThe outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergySubstituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaThe biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaThr 163 phosphorylation causes Mcl-1 stabilization when degradation is independent of the adjacent GSK3-targeted phosphodegron, promoting drug resistance in cancerThe splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioImpact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia.Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical riskDietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia.Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance.VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia.Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.Overexpression of Mcl-1L splice variant is associated with poor prognosis and chemoresistance in oral cancers.Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemiaThe B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells.Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia.The essential role of evasion from cell death in cancer.Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation.LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target.Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL.miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)Broad targeting of resistance to apoptosis in cancer.Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction.
P2860
Q24633394-5E16EF6E-F368-4623-AF44-69FB7A30B0CEQ26771601-7B0863B5-108A-46C8-AB09-048B39A5F23FQ26781203-CEB16D58-8E15-4F8D-9DAE-E1223A5CC29DQ26781895-1197356E-BFF2-4AD8-96B9-F6E74874D2B3Q26865760-E95217F4-4CBA-4F63-9AA4-0D2FC626B87AQ27675842-EF660179-3824-4773-9B35-F69B4DE55630Q28075504-05FFBCC0-75EB-4087-8422-067BE155B553Q28075683-9604918D-1273-435F-A229-453AA8C601F7Q28484291-5D23B896-D2C7-463D-8E7C-D8956630BC20Q30395427-59192227-91D9-4D02-BCF4-7D7ED4B66556Q33882849-22F84393-EFA8-414C-BDB4-4FE9C3CC7E40Q34056568-4FA257D8-85F5-4D79-AF08-C7CE4E3A6033Q34122323-3CDC3322-8BA8-4C0D-B513-16E2AE0644F3Q34173253-D7A12234-E13E-468A-88DB-893FB5F46B0CQ34202277-7C605F80-AD42-4397-8D60-F9C47B400255Q34231324-0E98B895-4905-4D16-B275-61147A646F4EQ34255118-696774AC-6D10-4F42-9968-96B5F64E71FEQ34285688-12A6481C-5460-4F98-AAA6-00DB98FC9402Q34369809-83C0F552-DA4A-4133-9C4D-0A53B8F679E8Q34382986-0BF53FA5-E58D-4C48-8BBE-2B29F6668CEBQ34508337-8F466FFF-AAC2-42EB-9771-E0678E7D7B07Q34541989-801923BF-1359-4318-A971-741B56452C28Q34568840-02D79F18-08F9-4A81-B94C-820F637DDD18Q35011166-14587E21-EBFF-41FE-9D56-94931CA1D04DQ35022490-E9F2A782-0D19-4931-933C-7E3591DD5736Q35083049-4C39539A-74F6-42AD-A497-9374BFEFF6D7Q35089766-EF67B38C-46C5-4F87-B064-6160AB4DE8EDQ35125652-980F26B1-7418-4579-9735-9E5EC9F00469Q35143479-59B23C6C-F118-442E-94C3-AADF0DA70ECCQ35266213-4720E9BF-D541-46F2-8357-1FA5C3059B45Q35483640-61079E35-BEB0-471E-AA34-3236ED14D99CQ35550068-CD92D07F-BBA8-42D0-8E6D-0D1CD22C1CC1Q36111609-1ADF3188-2068-4C97-BD92-F9E08ACF531EQ36140862-D2333909-D480-4CC5-980C-277F13171FC1Q36247617-9EF43C8A-FE2E-47FC-828D-058252C5A7E3Q36254232-58695564-C624-4C8E-9B98-A186DCB2BEE6Q36349985-11128984-401E-4BDB-81DD-3B58CC2A2AF2Q36483749-324F50CB-D2A2-4FFB-BAE4-21D502E5C499Q36688994-0F83D791-7433-46BE-987F-B0254E484A25Q36785683-B882404F-62DA-483D-8B0F-19E883FBE937
P2860
Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Mcl-1 expression has in vitro ...... other poor prognostic markers.
@en
Mcl-1 expression has in vitro ...... other poor prognostic markers.
@nl
type
label
Mcl-1 expression has in vitro ...... other poor prognostic markers.
@en
Mcl-1 expression has in vitro ...... other poor prognostic markers.
@nl
prefLabel
Mcl-1 expression has in vitro ...... other poor prognostic markers.
@en
Mcl-1 expression has in vitro ...... other poor prognostic markers.
@nl
P2093
P1433
P1476
Mcl-1 expression has in vitro ...... other poor prognostic markers
@en
P2093
Belinda Austen
Chris Fegan
Chris Pepper
Jane Starczynski
Laura Hooper
Louise Hiller
Paul Brennan
Rachel Ward
Saman Hewamana
P304
P356
10.1182/BLOOD-2008-05-157131
P407
P577
2008-07-03T00:00:00Z